首页> 外文期刊>Respiration: International Review of Thoracic Diseases >Serum concentrations of lignocaine before, during and after fiberoptic bronchoscopy (see comments)
【24h】

Serum concentrations of lignocaine before, during and after fiberoptic bronchoscopy (see comments)

机译:纤维支气管镜检查之前,期间和之后血清中利多卡因的浓度(参见评论)

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Lignocaine is commonly used for local anesthesia during fiberoptic bronchoscopy (FOB). Several studies have reported the peak serum concentration of lignocaine in relation to time, but most of them did not specify the administered dose of lignocaine gel and its possible correlation with peak serum concentration. OBJECTIVE: The aim of our study was to record the plasma concentrations of lignocaine before, during and after FOB and to evaluate whether the doses for nasal and tracheobronchial anesthesia have any correlation with the peak serum concentrations of the drug. METHODS: Twelve patients with no comorbid conditions undergoing FOB were studied. Lignocaine was administered as a 2% solution using a larynx syringe, 2% gel (mean dose 182.5 +/- 15 mg) and finally 2% solution through the bronchoscope (mean dose 339 +/- 12 mg). Total dose was 622 +/- 20 mg. Venous blood samples were taken before the beginning of local anesthesia and then at 5, 10, 20, 60, 90 and 120 min thereafter. RESULTS: Our results showed that peak plasma concentrations of lignocaine were observed in 8 patients 20 min after the beginning of local anesthesia, in 3 patients 30 min afterwards and in 1 patient 60 min afterwards (2.15 +/- 0.4 microg/ml, 1.9 +/- 0.3 microg/ml, 1. 81 microg/ml, respectively). None of our patients exceeded the critical level of toxicity (5 microg/ml). Both the total and tracheobronchial doses of lignocaine were significantly correlated with peak serum concentration (r = 0.63, p = 0.05 and r = 0.64, p = 0.02, respectively). No correlation was found between the dose for nasal anesthesia and peak serum concentration. No adverse reactions were observed. CONCLUSIONS: In conclusion our data show that although the amount of lignocaine used in this study exceeded the recommended highest dose (400 mg) in all patients, no toxic levels were observed. Peak plasma concentrations were found within 20-30 min from the beginning of local anesthesia. The dose for the anesthesia of nasal mucosa represented a significant percentage of the total dose, but did not correlate with the peak serum concentration of the drug. Copyright 2000 S. Karger AG, Basel
机译:背景:利多卡因通常用于纤维支气管镜检查(FOB)期间的局部麻醉。几项研究报告了利诺卡因的峰值血清浓度与时间的关系,但大多数研究并未指定利诺卡因凝胶的给药剂量及其与峰值血清浓度的可能关系。目的:我们的研究目的是记录利福卡因在FOB之前,期间和之后的血浆浓度,并评估鼻腔和气管支气管麻醉的剂量是否与药物的峰值血清浓度有任何相关性。方法:对12名无合并症的患者进行FOB研究。使用喉头注射器以2%的溶液,2%的凝胶剂(平均剂量182.5 +/- 15 mg),最后通过支气管镜以2%的溶液剂(平均剂量339 +/- 12 mg)施用利多卡因。总剂量为622 +/- 20mg。在开始局部麻醉之前采集静脉血样,然后在5、10、20、60、90和120分钟采集。结果:我们的结果表明,局部麻醉开始后20分钟内8例患者,术后30分钟内3例患者和术后60分钟内1例患者中观察到了利多卡因的血浆峰值浓度(2.15 +/- 0.4 microg / ml,1.9 +分别为0.3微克/毫升,1。81微克/毫升)。我们的患者均未超过毒性的临界水平(5微克/毫升)。利多卡因的总剂量和气管支气管剂量均与峰值血药浓度显着相关(分别为r = 0.63,p = 0.05和r = 0.64,p = 0.02)。鼻麻醉剂量和血清峰值浓度之间没有相关性。没有观察到不良反应。结论:总的来说,我们的数据表明,尽管本研究中使用的利多卡因的量超过了所有患者推荐的最高剂量(400 mg),但未观察到毒性水平。在局部麻醉开始后的20-30分钟内发现血浆峰值浓度。鼻粘膜麻醉的剂量占总剂量的很大百分比,但与药物的峰值血清浓度无关。版权所有2000 S. Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号